BPC-157 (Body Protection Compound-157) is a 15-amino acid synthetic peptide derived from a protective protein found in human gastric juice. It is one of the most widely studied tissue-repair peptides in published preclinical literature, with demonstrated healing activity across skin, tendon, ligament, muscle, bone, nerve, cornea, and gastrointestinal tissues in animal models.
Despite not yet receiving FDA approval, BPC-157 has been previously employed in human clinical trials for ulcerative colitis and multiple sclerosis, with no reported toxicity — the LD1 (lethal dose for 1% of subjects) was never achieved in safety testing. This guide covers the compound’s mechanisms, published research, and practical information for researchers.
Chemical Profile
Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 amino acids) | CAS: 137525-51-0 | Molecular Weight: 1,419.53 Da | Stability: Highly stable — resistant to hydrolysis and enzymatic digestion, even in gastric juice | Solubility: Freely soluble in water; no carrier required
How BPC-157 Works: Mechanisms of Action
Angiogenesis (New Blood Vessel Formation)
BPC-157’s pro-angiogenic activity is one of its best-characterized mechanisms. Published research demonstrates that BPC-157 is associated with VEGFR2 (vascular endothelial growth factor receptor 2) activation and upregulation (Hsieh et al., 2017, J Mol Med). New blood vessel formation is a critical early step in tissue repair — without adequate blood supply, damaged tissue cannot receive the oxygen and nutrients required for healing. BPC-157 appears to accelerate this vascular response at injury sites.
Tendon and Connective Tissue Repair
BPC-157 significantly accelerates tendon fibroblast outgrowth from tendon explants in culture. While it does not directly stimulate cell proliferation, it increases cell survival under oxidative stress (H₂O₂ exposure) and promotes dose-dependent cell migration via the FAK-paxillin signaling pathway (Chang et al., 2011, J Appl Physiol). F-actin formation is induced in BPC-157-treated fibroblasts, and phosphorylation of both FAK and paxillin increases in a dose-dependent manner. These mechanisms — enhanced migration, improved survival under stress, and cytoskeletal reorganization — are directly relevant to tendon, ligament, and soft tissue healing.
Wound Healing
BPC-157 accelerates healing across a remarkable range of wound types in animal models. Published studies demonstrate activity in incisional and excisional wounds, deep partial-thickness burns (outperforming silver sulfadiazine cream), diabetic ulcers, alkali burns, and complex fistulas including gastrocutaneous, esophagocutaneous, and colocutaneous fistulas (Seiwerth et al., 2021, Front Pharmacol). The wound healing mechanism involves resolution of vessel constriction, stabilization of the primary platelet plug, formation and resolution of fibrin mesh, and rapid upregulation of growth factor gene expression in wound tissue.
Nitric Oxide System Modulation
BPC-157 interacts with the nitric oxide (NO) system, which plays a central role in regulating blood vessel tone, inflammation, and tissue repair signaling. This NO modulation appears to mediate many of BPC-157’s vascular and anti-inflammatory effects.
Gastrointestinal Protection
As a peptide originally isolated from gastric juice, BPC-157 demonstrates particular potency in gastrointestinal contexts. It has been shown to protect against NSAID-induced cytotoxicity by stabilizing intestinal permeability and enhancing cytoprotective mechanisms (Park et al., 2020, Curr Pharm Des). It counteracts gastric lesions induced by various agents including alcohol, capsaicin, and stress.
Neuroprotective Activity
Published studies report that BPC-157 exhibits effects on the central nervous system, including interactions with dopaminergic and serotonergic pathways. It has demonstrated protective effects against nerve damage in animal models and appears to promote nerve fiber regeneration.
Published Research Highlights
Burn Wound Healing (Mikus et al., 2001)
In mice with deep partial-thickness burns covering 20% of total body area, BPC-157 applied topically as a cream or administered systemically via injection significantly improved healing outcomes compared to controls. BPC-157-treated mice showed decreased inflammatory cell infiltration, lower water content in burned skin, and increased breaking strength. The peptide consistently outperformed silver sulfadiazine cream (the standard burn treatment) and systemic corticosteroids.
Achilles Tendon Healing (Chang et al., 2011)
BPC-157 accelerated outgrowth of tendon fibroblasts from tendon explants, increased cell survival under oxidative stress, and promoted dose-dependent cell migration. The mechanism was identified as activation of the FAK-paxillin pathway, with increased F-actin formation in treated cells.
Musculoskeletal Soft Tissue Review (Gwyer et al., 2019)
A comprehensive review published in Cell and Tissue Research concluded that BPC-157 has “huge potential” as a therapy for hypovascular and hypocellular soft tissues such as tendons and ligaments. The review noted beneficial effects not only in direct trauma models but also in systemic insult models, with remarkably few reported adverse reactions across the published literature.
Systematic Review in Sports Medicine (2025)
A systematic review from an orthopedic sports medicine perspective, searching PubMed, Cochrane, and Embase databases from inception to June 2024, synthesized the BPC-157 literature and confirmed its potential for promoting healing in fractures, tendon ruptures, ligament tears, and muscle injuries, while noting the absence of controlled human clinical trials.
Safety Profile
Published toxicology data is notably favorable. A 2020 preclinical safety evaluation (Xu et al., Regul Toxicol Pharmacol) confirmed a favorable safety profile. BPC-157 has been previously employed in human clinical trials for ulcerative colitis and multiple sclerosis with no reported toxicity. The lethal dose threshold (LD1) was never achieved in animal safety testing — meaning researchers could not find a dose lethal to even 1% of test subjects.
BPC-157 vs. Other Repair Peptides
| Property | BPC-157 | TB-500 | GHK-Cu |
|---|---|---|---|
| Primary mechanism | VEGFR2 angiogenesis + NO modulation | Actin regulation + cell migration | Collagen synthesis + gene modulation |
| Best studied for | Gut, tendon, wound healing | Muscle, cardiac, connective tissue | Skin, collagen, anti-aging |
| Origin | Human gastric juice | Thymic tissue (ubiquitous) | Human blood plasma |
| Human trial history | UC and MS trials conducted | Limited | Cosmetic clinical studies |
| Complementary with | TB-500, GHK-Cu, KPV | BPC-157, GHK-Cu | BPC-157, TB-500 |
Many researchers study BPC-157 alongside TB-500 and GHK-Cu because they target complementary repair pathways. PSPeptides offers pre-combined blends that include BPC-157:
- GLOW — BPC-157 (10mg) + GHK-Cu (50mg) + TB-500 (10mg)
- KLOW — BPC-157 (10mg) + GHK-Cu (50mg) + TB-500 (10mg) + KPV (10mg)
Frequently Asked Questions
What is BPC-157 used for in research?
BPC-157 is primarily studied for tissue repair including wound healing, tendon and ligament regeneration, gastrointestinal protection, burn healing, and neuroprotective effects. It is one of the most broadly active repair peptides in published preclinical literature.
Is BPC-157 FDA-approved?
No. BPC-157 is not FDA-approved for any clinical indication. It has been previously used in human clinical trials for ulcerative colitis and multiple sclerosis but has not completed the regulatory approval process. It is sold exclusively for laboratory research purposes.
What makes BPC-157 different from other healing peptides?
BPC-157 is uniquely stable — resistant to degradation by gastric enzymes, unlike most peptides — and demonstrates activity across an unusually broad range of tissue types. Its primary mechanisms (VEGFR2-mediated angiogenesis and NO system modulation) are distinct from those of TB-500 (actin regulation) and GHK-Cu (collagen synthesis), which is why researchers often study them in combination.
Has any toxicity been reported?
Published safety data is remarkably favorable. The LD1 was never achieved in animal toxicology studies, and human clinical trials reported no toxicity. A 2020 preclinical safety evaluation confirmed a favorable safety profile at research-relevant doses.
References
- Seiwerth S, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol. 2021;12:627533.
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing. J Appl Physiol. 2011;110:774-780.
- Mikus D, et al. Pentadecapeptide BPC 157 cream improves burn-wound healing. Burns. 2001;27:817-827.
- Gwyer D, et al. Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159.
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation. J Mol Med. 2017;95:323-333.
- Park JM, et al. BPC 157 rescued NSAID-cytotoxicity via stabilizing intestinal permeability. Curr Pharm Des. 2020;26:2971-2981.
- Xu C, et al. Preclinical safety evaluation of body protective compound-157. Regul Toxicol Pharmacol. 2020;114:104665.
All products mentioned are intended for laboratory research use only. Not for human consumption.
PSPeptides — US Made & Shipped | Third-Party Tested | 99%+ Purity | Same-Day Shipping